Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Arbeitsgemeinschaft medikamentoese Tumortherapie
ClinicalTrials.gov Identifier:
NCT01703364
First received: October 4, 2012
Last updated: September 9, 2014
Last verified: September 2014
  Purpose

This is a trial in patients with previously untreated CLL. Eligible patients will receive Lenalidomide with a backbone of Fludarabine and Rituximab for 6 therapy cycles. Lenalidomide will be increased by dose steps of 5 mg every cycle in the absence of limiting toxicity. If limiting toxicity ensues the patients will be treated with last tolerable dose for the remainder of the 6 treatment cycles.

The first 5 patients will start with dose level 5 mg Lenalidomide and further escalating dose. After the fifth patient is included in the study, enrolment will be interrupted until this patient has finished his first treatment cycle. A safety board will evaluate the toxicities of the first 5 patients. If there are more than 2 patients experiencing a dose limiting toxicity (DLT) in the first treatment cycle, the starting dose will not be escalated and further 5 patients will be enrolled with a starting dose of 5 mg Lenalidomide. If only 2 or less patients experience a DLT in the first treatment cycle, the next 5 patients will start the treatment with 10 mg Lenalidomide.

The rational for the higher starting doses stems from the lack of tumor lysis or tumor flare toxicity in this combination on the one hand and from the observation that the very slow escalation from 2,5 mg on led to a lack of efficacy in monotherapy trials due to early progression in a relevant number of cases. The increase of the Lenalidomide dosage should result in an increased efficacy especially at the beginning and a higher cumulative dose of Lenalidomide.

The identification of patients intolerant to Lenalidomide by immunophenotyping of the T cells for validation is also part of this trial, because intolerance seems to be not dose dependent but may be caused by T cell activation. Therefore, early identification of patients intolerant to this form of modern immunochemotherapy and establishing efficient Lenalidomide based combination therapy is an important part of improvement of current CLL treatment.


Condition Intervention Phase
CLL
Chronic Lymphocytic Leukemia
Drug: Lenalidomide
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Escalating Starting Dose of Lenalidomide and Concomitant Evaluation of Safety and Efficacy

Resource links provided by NLM:


Further study details as provided by Arbeitsgemeinschaft medikamentoese Tumortherapie:

Primary Outcome Measures:
  • Tolerability of escalated starting dose [ Time Frame: 12 month, 20 month ] [ Designated as safety issue: Yes ]
    Interim analysis after completion of cylce 1 of the first 5 patients, final analysis after last pastient last visit Metrics: Number of patients experiencing defined dose limiting toxicities during cycle 1


Secondary Outcome Measures:
  • Establishment of maximal tolerated dose (MTD) of Lenalidomide in combination with FR [ Time Frame: 20 month ] [ Designated as safety issue: No ]
  • Time to MTD [ Time Frame: 20 month ] [ Designated as safety issue: No ]
  • Safety profile of the FRL combination [ Time Frame: 20 month ] [ Designated as safety issue: No ]
    Analysis of occuring adverse events during the study treatment according to Common Terminology Criteria for Adverse Events (CTCAE)

  • Response rates in all phases by 4-colour flow cytometric and ASO-PCR MRD analysis [ Time Frame: 20 month ] [ Designated as safety issue: No ]
  • Risk factor analysis (FISH cytogenetics, CD38/ZAP-70 expression, mutation status) [ Time Frame: 20 month ] [ Designated as safety issue: No ]
  • Longitudinal definition of T cell subsets (including prognostic EM T cells and Treg cells)+/- PD1 [ Time Frame: 20 month ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: September 2012
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Lenalidomide

    Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs

    Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days

    Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days

    Other Name: Revlimid
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed written informed consent
  • Male or female ≥ 18 years of age
  • CLL (as determined by CD23+, CD5+, CD19+)
  • Treatment indication as defined by the NCI Workshop criteria (see appendix 6 and reference 10)
  • ECOG ≤ 2
  • No previous treatment of the CLL by chemotherapy, radiotherapy (except localized radiotherapy of 1 lymphatic area) or immunotherapy
  • Life expectancy > 6 months (except prognosis due to high risk CLL)

Exclusion Criteria:

  • Active bacterial, viral or fungal infection
  • Positivity for HIV, Hepatitis B or C
  • Patients with known history of thromboembolic events
  • Reduced organ functions and bone marrow dysfunction not due to CLL
  • Creatinine clearance of below 30 ml/min
  • Patients with known history of thromboembolic events
  • Patients with a history of other malignancies within 2 years prior to study entry (except for adequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low grade, early stage localized prostate cancer treated surgically with curative intent; good prognosis DCIS of the breast treated with lumpectomy alone with curative intent)
  • Patients with medical co-morbid conditions that would require long term use (> 1 month) of systemic corticosteroids during study treatment
  • Patients with a history of severe cardiac disease; e.g. NYHA Functional Class III or IV heart failure, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, or unstable angina
  • Other known co-morbidity with the potential to dominate survival
  • Transformation to aggressive B-cell malignancy (e.g., large B-cell lymphoma, Richter's syndrome, or prolymphocytic leukemia (PLL))
  • Hypersensitivity with anaphylactic reaction to humanised monoclonal antibodies or any of the applied drugs
  • Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not indicated in the study protocol
  • Administration of any investigational agent(s) within 4 weeks prior to entry
  • Pregnancy or lactation
  • Medical or psychological condition which in the opinion of the Investigator would not permit the patient to complete the study or sign meaningful informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01703364

Locations
Austria
Universitätsklinik für Innere Medizin Innsbruck, Klinische Abteilung für Hämatologie und Onkologie
Innsbruck, Tirol, Austria, 6020
Universitätsklinik der PMU Salzburg, Univ-Klinik für Innere Medizin III
Salzburg, Austria, 5020
Sponsors and Collaborators
Arbeitsgemeinschaft medikamentoese Tumortherapie
Celgene Corporation
  More Information

Additional Information:
AGMT  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Arbeitsgemeinschaft medikamentoese Tumortherapie
ClinicalTrials.gov Identifier: NCT01703364     History of Changes
Other Study ID Numbers: AGMT_CLL-9, 2011-004912-43
Study First Received: October 4, 2012
Last Updated: September 9, 2014
Health Authority: Austria: Agency for Health and Food Safety

Keywords provided by Arbeitsgemeinschaft medikamentoese Tumortherapie:
CLL
Lenalidomide
lenalidomide
Revlimid
AGMT
T cell

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Fludarabine
Fludarabine phosphate
Lenalidomide
Rituximab
Thalidomide
Vidarabine Phosphate
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents

ClinicalTrials.gov processed this record on October 23, 2014